Soluble biomarkers of immune activation and inflammation in HIV infection: Impact of 2 years of effective first-line combination antiretroviral therapy

HIV Medicine

Volumn 16, Issue 9, 2015, Pages 553-562

  Hattab, S ^a   Guiguet, M ^a   Carcelain, G ^b,c,d   Fourati, S ^a,d   Guihot, A ^b,c,d   Autran, B ^b,c,d   Caby, F ^a,d   Marcelin, A G ^a,d   Costagliola, D ^a   Katlama, C ^a,d  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b Assistance publique Hôpitaux de Paris   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Age; Biomarkers; Combination antiretroviral therapy; HIV; Immune activation; Inflammation

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; BIOLOGICAL MARKER; CD14 ANTIGEN; CXCL9 CHEMOKINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CXCL10 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; AGE; BLOOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84946163423     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12257     Document Type: Article

References (41)

1. Delaugerre C, Ghosn J, Lacombe JM etal. Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011; Rome. Abstract TUPDB0104.
2. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
3. Katlama C, Deeks SG, Autran B etal. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-2117.
4. Hunt PW, Brenchley J, Sinclair E etal. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133.
5. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231-241.
6. Lederman MM, Calabrese L, Funderburg NT etal. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226.
7. Hunt PW, Sinclair E, Rodriguez B etal. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210: 1228-1238.
8. De Luca A, de Gaetano Donati K, Colafigli M etal. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case - control study. BMC Infect Dis 2013; 13: 414.
9. McComsey GA, Kitch D, Sax PE etal. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014; 65: 167-174.
10. Tenorio AR, Zheng Y, Bosch RJ etal. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210: 1248-1259.
11. Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
12. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
13. Mavigner M, Delobel P, Cazabat M etal. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 2009; 4: e7658.
14. Hunt PW, Martin JN, Sinclair E etal. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483.
15. Petrara MR, Cattelan AM, Zanchetta M etal. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol 2012; 53: 195-200.
16. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-666.
17. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21: 6-13.
18. Liovat A-S, Rey-Cuillé M-A, Lécuroux C etal. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS ONE 2012; 7: e46143.
19. Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
20. Smith KY, Patel P, Fine D etal. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547-1556.
21. McComsey GA, Kitch D, Daar ES etal. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26: 1371-1385.
22. Funderburg N, Kalinowska M, Eason J etal. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE 2010; 5: e13188.
23. Palella FJ Jr, Gange SJ, Benning L etal. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24: 1657-1665.
24. Cassol E, Malfeld S, Mahasha P etal. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202: 723-733.
25. Taiwo B, Matining RM, Zheng L etal. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother 2013; 68: 1857-1861.
26. Boulware DR, Hullsiek KH, Puronen CE etal. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203: 1637-1646.
27. Marks MA, Rabkin CS, Engels EA etal. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2013; 27: 469-474.
28. Kamat A, Misra V, Cassol E etal. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS ONE 2012; 7: e30881.
29. Cohen Stuart JW, Hazebergh MD, Hamann D etal. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000; 25: 203-211.
30. Keating SM, Golub ET, Nowicki M etal. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25: 1823-1832.
31. Simmons RP, Scully EP, Groden EE etal. HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS 2013; 27: 2505-2517.
32. Kelesidis T, Tran TTT, McComsey GA etal. Comparison of effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on biomarkers of systemic inflammation, macrophage and T cell activation: ACTG A5260s. 20th International AIDS Conference. 2014; Melbourne. Abstract WEAB0106LB.
33. Longenecker CT, Jiang Y, Orringer CE etal. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28: 969-977.
34. Danesh J, Kaptoge S, Mann AG etal. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
35. Appay V, Fastenackels S, Katlama C etal. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS 2011; 25: 1813-1822.
36. Alcaide ML, Parmigiani A, Pallikkuth S etal. Immune activation in HIV-infected aging women on antiretrovirals - implications for age-associated comorbidities: a cross-sectional pilot study. PLoS ONE 2013; 8: e63804.
37. Grabar S, Kousignian I, Sobel A etal. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18: 2029-2038.
38. Hattab S, Guihot A, Guiguet M etal. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis 2014; 14: 122.
39. Grennan JT, Loutfy MR, Su D etal. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205: 1230-1238.
40. Taiwo B, Hunt PW, Gandhi RT etal. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 63: 101-104.
41. Althoff KN, Gebo KA, Gange SJ etal. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010; 7: 45.